Emjard 10

Indications

Emjard serves the following purposes:

• As a complement to dietary and exercise regimens, it aids in enhancing glycemic control among adults diagnosed with type 2 diabetes mellitus.
• It’s employed to mitigate the risk of cardiovascular mortality in adult patients grappling with type 2 diabetes mellitus and confirmed cardiovascular ailment.

Pharmacology

Empagliflozin, a sodium glucose co-transporter-2 (SGLT-2) inhibitor, plays a pivotal role in inhibiting SGLT2 co-transporters. These co-transporters facilitate the reabsorption of glucose from the glomerular filtrate in the kidney. By inhibiting SGLT2, Empagliflozin fosters a glucuretic effect, reducing renal absorption and lowering the renal threshold for glucose. Consequently, this prompts increased glucose excretion, contributing to diminished hyperglycemia, weight loss, and blood pressure reduction.

Dosage & Administration

The recommended dosage of Empagliflozin stands at 10 mg, administered once daily in the morning, with or without food. For patients exhibiting tolerance to Empagliflozin, the dosage may be elevated to 25 mg once daily. Prior to initiating Empagliflozin in patients with volume depletion, rectification of this condition is advised.

Interactions

• Co-administration of Emjard with diuretics has been observed to amplify urine volume.
• Concurrent use of Emjard with insulin or insulin secretagogues heightens the risk of hypoglycemia.
• Monitoring glycemic control with urine glucose tests is not recommended for patients consuming SGLT2 inhibitors due to increased urinary glucose excretion, which leads to positive urine glucose test results. Alternative methods should be employed to monitor glycemic control.
• Relying on the 1,5-anhydroglucitol (1,5-AG) assay to monitor glycemic control is not advisable for patients taking SGLT2 inhibitors, as measurements of 1,5-AG are unreliable in this context. Alternative monitoring methods are recommended.

Contraindications

Empagliflozin is contraindicated in individuals with a history of serious hypersensitivity reactions to Empagliflozin or any of its constituents, severe renal impairment, end-stage renal disease, or undergoing dialysis.

Side Effects

Common adverse reactions associated with Emjard encompass urinary tract infections, female genital mycotic infections, dehydration, hypotension, weakness, dizziness, and increased thirst.

Pregnancy & Lactation

There’s a dearth of adequate and well-controlled studies regarding Empagliflozin use in pregnant women. Its usage during pregnancy is warranted only if the potential benefits outweigh the potential risks to the fetus. The excretion of Empagliflozin in human milk remains unknown, thus its use during breastfeeding is not recommended.

Precautions & Warnings

It’s recommended to evaluate renal function prior to initiating Emjard and at regular intervals thereafter. Emjard should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73 m2. No dosage adjustment is deemed necessary for patients with an eGFR greater than or equal to 45 ml/min/1.73 m2.

Overdose Effects

In instances of Emjard overdose, conventional supportive measures should be employed, such as removing unabsorbed material from the gastrointestinal tract, clinical monitoring, and implementing supportive treatment. Notably, the removal of Emjard via hemodialysis hasn’t been explored.

Therapeutic Class

Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage Conditions

Store in a cool and dry place (below 30°C), shielded from light and moisture, and keep out of the reach of children.

Chemical Structure

• Molecular Formula: C23H27ClO7
• Chemical Structure: Empagliflozin’s Chemical Structure

Common Questions about Emjard 10 mg Tablet

• What is Emjard 10 mg Tablet?
  • Emjard 10 mg Tablet is an SGLT-2 inhibitor that curtails glucose reabsorption from the kidneys.
• What is Emjard 10 mg Tablet used for?
  • Emjard 10 mg Tablet is predominantly employed to enhance glycemic control in adults.
• Are there any pregnancy warnings?
  • Emjard 10 mg Tablet may pose risks during pregnancy.
• Are there any breastfeeding warnings?
  • Emjard 10 mg Tablet is likely unsafe during breastfeeding.
• Does this affect kidney function?
  • Emjard 10 mg Tablet should be approached cautiously in patients with underlying kidney conditions.
• Does this affect liver function?
  • No dose adjustment is deemed necessary for patients with mild to moderate liver disease.

Quick Tips

• Emjard 10 mg Tablet, either alone or combined with other diabetes medications, is instrumental in regulating blood sugar levels and averting long-term complications.
• Emjard 10 mg Tablet may induce excessive fluid loss (dehydration) or increased urination frequency. It’s imperative to stay hydrated by consuming ample water.
• When administered with other antidiabetic medications or alcohol, or in the event of delayed or missed meals, Emjard 10 mg Tablet may precipitate hypoglycemia (low blood sugar levels).
• It’s advisable to carry sugary snacks or fruit juice to counteract hypoglycemia symptoms, such as cold sweats, pallor, tremors, and anxiety.
• Both females and males taking Emjard 10 mg Tablet may be susceptible to genital fungal and/or urinary tract infections (UTIs), hence practicing good hygiene is crucial.
• Regular blood sugar monitoring is essential while on Emjard 10 mg Tablet.
• Promptly inform your healthcare provider if you experience persistent dizziness, joint discomfort, flu-like symptoms, or unexplained nausea/vomiting.